A questionnaire survey on real-world treatment practices in patients receiving inhaled treprostinil therapy

A questionnaire survey on real-world treatment practices in patients receiving inhaled treprostinil therapy - A questionnaire survey on real-world treatment practices in patients receiving inhaled treprostinil therapy

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

JPRN

Registry ID

JPRN-UMIN000060887

Enrollment

200

Registered

2026-03-31

Start date

2026-04-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Pulmonary arterial hypertension (PAH), pulmonary hypertension associated with interstitial lung disease (PH-ILD)

Interventions

None listed

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1) Patients who have provided informed consent. 2) Patients who have been receiving inhaled treprostinil therapy for at least 30 days at the time of survey response.

Exclusion criteria

Exclusion criteria: 1) Patients younger than 18 years of age.

Design outcomes

Primary

Measure	Time frame
1) Satisfaction with inhaled treprostinil therapy 2) Changes in symptoms and impact on daily life after initiation of inhaled treprostinil therapy 3) Patient-reported challenges related to inhaled treprostinil therapy	—

Countries

Japan

Contacts

Public ContactTakashi Orido

Mochida Pharmaceutical Co., Ltd. Medical Affairs

takashi.orido@mochida.co.jp03-3225-5138

Outcome results